Mark Cochran Email and Phone Number

Work with faculty on commercialization ideas

Neuro-Innovators (NIV) is a Pittsburgh, Pennsylvania-based clinical stage drug company focused on engineering drugs to accelerate Brain Neuroplasticity (i.e., the capacity of the brain to rebuild, rewire, and recover) for patients suffering with brain injuries and diseases. We believe that neuroplasticity – the remodeling the of brain after impairments from injury or disease – will be critical to combatting brain impairments related to dementia, depression, movement disorders, immune-system attacks, psychiatric illness, and cognition deficits. These ailments present large burdens on individuals, family, communities, nations, and the globe.

Founded in December 2021, Neuro-Innovators, LLC (NIV), is commercializing novel drug combinations that enhance neuroplasticity and brain repair.Little work has been, or is being done, with existing drugs known to help the rewiring of our brains, and NIV is taking the lead in mapping this massive white space. It has already filed two patent applications with more ready to go.Our initial focus is chronic stroke (3 or more months post stroke event) and its lingering deficits. The ~ 6 million US victims currently have no practical hope of getting better and we estimate this total addressable market to be ~$60 billion. Importantly stroke rehabilitation is associated with multiple objective metrics, and such metrics are critical to successful FDA approvals. https://www.linkedin.com/company/neuro-innovators/Send me an email if you wish to learn more.

Business Development, fund raising, investor awareness, operational management

Managing Director of a new operating division entitled Johns Hopkins HealthCare Solutions. The key objective of this group is to generate new revenue and funding streams through establishing new business and partnerships involving JHM and faculty, and to manage them. Created a sustainable business growing revenues from $1.5M to $18M. Now retired.

BRNI is a unique, independent, non-profit institute dedicated to the study of both memory and memory disorders. Its mission is to advance state-of-the-art scientific research of memory and memory disorders, particularly Alzheimer’s disease, for purposes of prevention, diagnosis, and treatment, and to promote translation of resulting discoveries to practical medical applications. My role was to manage the efforts to build a quality research institution funded through a combination of grants, donations and pharmaceutical collaborations.

Board position as early stage investor

A venture fund dedicated to investing in companies involved in the development and marketing of drugs, devices, therapeutics, diagnostics and other medical technologies for the clinical Neuroscience markets. I was one of two managing partners.

Board seat as early stage investor

As an Officer and Vice President of the MDS US-subsidiary, I established an office for MDS in the SF Bay area, and sourced, evaluated and made investment decisions on behalf of MDS in the health care field. I also managed a number of business development efforts on behalf of some of their portfolio companies.

Guided and directed the planning and business development activities of the Biotechnology business including development of overall business strategy, product plans, research priorities, licensing, monitoring of the competitive environment, and assessment of business opportunities to assure the attainment of the long term strategy and short-term business objectives. Worldwide responsibility for interfacing with the biotechnology industry to source and assess innovative products and technologies for potential in-licensing or collaboration. The position reported to the Head of Biotechnology. Reporting to the position was a staff of 15 with the functions of Licensing, Strategic Planning and Project Management.

Guided and directed the planning and business development activities of the Biotechnology business including development of overall business strategy, product plans, research priorities, licensing, monitoring of the competitive environment, and assessment of business opportunities to assure the attainment of the long term strategy and short-term business objectives. Worldwide responsibility for interfacing with the biotechnology industry to source and assess innovative products and technologies for potential in-licensing or collaboration. The position reported to the Head of Biotechnology. Reporting to the position was a staff of 15 with the functions of Licensing, Strategic Planning and Project Management

Guided and directed the planning and business development activities of the Biotechnology business including development of overall business strategy, product plans, research priorities, licensing, monitoring of the competitive environment, and assessment of business opportunities to assure the attainment of the long term strategy and short-term business objectives. Worldwide responsibility for interfacing with the biotechnology industry to source and assess innovative products and technologies for potential in-licensing or collaboration. The position reported to the Head of Biotechnology. Reporting to the position was a staff of 15 with the functions of Licensing, Strategic Planning and Project Management

Co-founder of this biopharmaceutical company (now called Protein Sciences www.proteinsciences.com), which was established to exploit the technical benefits of insect viruses as vectors and production systems. The company received public attention since it was the first to receive FDA approval for an AIDS vaccine clinical trial (IND: 1987). By 1989, MicroGeneSys had a staff of 43 including technical, regulatory affairs, marketing and administrative personnel. Projects included experimental vaccines for HIV-1, HIV-2, SIV-1, Malaria, Influenza, PIVIII, RSV, Dengue 1-4, HBV, JEV and Lyme disease, and a variety of cytokines and growth factors.